CROSS SYNC

CROSS SYNC, a Yokohama-based company founded in 2019, operates at the intersection of medical technology and data analytics, stemming from a Yokohama City University initiative. The company was established by Dr. Takayuki Manabe, an intensivist whose personal experiences in a clinical setting fueled a mission to eradicate preventable deaths. His background in critical care medicine provides the foundational expertise for the company's direction.

The firm's core business revolves around its medical data analytics software, "iBSEN," specifically engineered for hospital Intensive Care Units (ICUs). This system is designed to automate the continuous monitoring of a patient's vital signs and movements. By processing this information in real-time, iBSEN provides healthcare professionals with actionable intelligence. The primary benefit is the early detection of patient deterioration, enabling prompt intervention to reduce adverse outcomes, including mortality. The company's business model targets hospitals and healthcare facilities, offering both the patient management system and associated consulting services. In March 2024, the enhanced version, "iBSEN DX," received medical device certification, marking a significant milestone.

Financially, CROSS SYNC is in its Series A stage. In early 2025, the company secured approximately ¥150 million (around $966K) in a Series A2 funding round. This investment was led by medical equipment manufacturer Fukuda Denshi and venture capital firm IT-Farm Corporation. These funds are earmarked for the further development and functional expansion of the iBSEN DX software.

Keywords: medical data analytics, intensive care unit, ICU software, patient monitoring system, vital signs monitoring, clinical decision support, preventable deaths, iBSEN, Takayuki Manabe, Yokohama City University, HealthTech, clinical intelligence, patient deterioration, medical device software, Fukuda Denshi, IT-Farm Corporation